PDF(Pubmed)
Abstract：
UNASSIGNED: Several treatment options are available for anemia associated with chronic kidney disease (CKD); however, there remains a lack of awareness of physician and patient preferences regarding these treatments. We aimed to explore physicians\' and patients\' perceptions and preferences regarding the management of anemia of CKD in Japan.
UNASSIGNED: A web-based survey, including best-worst scaling (BWS), was conducted with physicians who had treated ≥1 patient with anemia of CKD in the preceding year, and with patients with CKD who self-reported a clinical diagnosis of anemia of CKD or low hemoglobin levels. A three-step approach was used comprising cognitive interviews, a pilot survey, and a main survey. The BWS survey results were analyzed using multinomial logit and hierarchical Bayesian models.
UNASSIGNED: The survey was completed by 906 participants: 103 patients (average age 60.6 years; 77.7% male) and 803 physicians (166 nephrologists, 214 cardiologists, 137 diabetologists, and 286 general internists). Almost all (96.0%) physicians surveyed considered anemia of CKD to be an important condition to treat. Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors had the highest treatment satisfaction among physicians, whereas patients had the highest satisfaction with both erythropoietin-stimulating agent therapy and HIF-PH inhibitors. Approximately one-third (35.9%) of patients surveyed indicated that they were receiving treatment. When comparing the relative importance of attributes and levels, physicians favored efficacy (particularly improvement in hemoglobin levels), whereas patients favored safety (particularly a lower rate of severe adverse events).
UNASSIGNED: Although a majority of physicians consider treatment of CKD-related anemia important, differences in the perceptions and usage of medications exist between medical specialties. Preferences for the management of anemia of CKD vary between physicians and patients; therefore, patient involvement in treatment decisions may help optimize outcomes.
UNASSIGNED: A web-based survey, including best-worst scaling (BWS), was conducted with physicians who had treated ≥1 patient with anemia of CKD in the preceding year, and with patients with CKD who self-reported a clinical diagnosis of anemia of CKD or low hemoglobin levels. A three-step approach was used comprising cognitive interviews, a pilot survey, and a main survey. The BWS survey results were analyzed using multinomial logit and hierarchical Bayesian models.
UNASSIGNED: The survey was completed by 906 participants: 103 patients (average age 60.6 years; 77.7% male) and 803 physicians (166 nephrologists, 214 cardiologists, 137 diabetologists, and 286 general internists). Almost all (96.0%) physicians surveyed considered anemia of CKD to be an important condition to treat. Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors had the highest treatment satisfaction among physicians, whereas patients had the highest satisfaction with both erythropoietin-stimulating agent therapy and HIF-PH inhibitors. Approximately one-third (35.9%) of patients surveyed indicated that they were receiving treatment. When comparing the relative importance of attributes and levels, physicians favored efficacy (particularly improvement in hemoglobin levels), whereas patients favored safety (particularly a lower rate of severe adverse events).
UNASSIGNED: Although a majority of physicians consider treatment of CKD-related anemia important, differences in the perceptions and usage of medications exist between medical specialties. Preferences for the management of anemia of CKD vary between physicians and patients; therefore, patient involvement in treatment decisions may help optimize outcomes.
摘要：
■多种治疗方案可用于治疗与慢性肾脏疾病（CKD）相关的贫血；然而，医生和患者对这些治疗的偏好仍然缺乏认识.我们旨在探讨日本医师和患者对CKD贫血管理的看法和偏好。
■一项基于网络的调查，包括最佳-最差缩放(BWS)，与前一年治疗≥1例CKD贫血患者的医生一起进行，以及自我报告临床诊断为CKD贫血或低血红蛋白水平的CKD患者。使用了三步方法，包括认知访谈，试点调查，和主要调查。使用多项logit和分层贝叶斯模型对BWS调查结果进行分析。
■调查由906名参与者完成：103名患者（平均年龄60.6岁；77.7％为男性）和803名医生（166名肾脏科医师，214位心脏病专家,137位糖尿病专家，和286名一般内科医生)。几乎所有（96.0％）接受调查的医生都认为CKD贫血是需要治疗的重要疾病。在医生中，缺氧诱导因子脯氨酸酰羟化酶（HIF-PH）抑制剂的治疗满意度最高。而患者对促红细胞生成素刺激剂治疗和HIF-PH抑制剂的满意度最高.接受调查的患者中约有三分之一（35.9％）表示正在接受治疗。比较属性和级别的相对重要性时，医生青睐疗效（特别是血红蛋白水平的改善），而患者倾向于安全性(尤其是较低的严重不良事件发生率).
■尽管大多数医生认为治疗CKD相关贫血很重要，医学专业之间对药物的认知和使用存在差异。对CKD贫血管理的偏好在医生和患者之间有所不同;因此，患者参与治疗决策可能有助于优化结果.
■一项基于网络的调查，包括最佳-最差缩放(BWS)，与前一年治疗≥1例CKD贫血患者的医生一起进行，以及自我报告临床诊断为CKD贫血或低血红蛋白水平的CKD患者。使用了三步方法，包括认知访谈，试点调查，和主要调查。使用多项logit和分层贝叶斯模型对BWS调查结果进行分析。
■调查由906名参与者完成：103名患者（平均年龄60.6岁；77.7％为男性）和803名医生（166名肾脏科医师，214位心脏病专家,137位糖尿病专家，和286名一般内科医生)。几乎所有（96.0％）接受调查的医生都认为CKD贫血是需要治疗的重要疾病。在医生中，缺氧诱导因子脯氨酸酰羟化酶（HIF-PH）抑制剂的治疗满意度最高。而患者对促红细胞生成素刺激剂治疗和HIF-PH抑制剂的满意度最高.接受调查的患者中约有三分之一（35.9％）表示正在接受治疗。比较属性和级别的相对重要性时，医生青睐疗效（特别是血红蛋白水平的改善），而患者倾向于安全性(尤其是较低的严重不良事件发生率).
■尽管大多数医生认为治疗CKD相关贫血很重要，医学专业之间对药物的认知和使用存在差异。对CKD贫血管理的偏好在医生和患者之间有所不同;因此，患者参与治疗决策可能有助于优化结果.
